ARBUTUS BIOPHARMA CORPORATION
58Patents
56Active
58Granted
56Portfolio score
Filing activity: Dec 7, 2010 → Jan 12, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9394234B2 | Lipid formulations | Emerging Cross-Sectional Technologies | 99 | Active |
| US9682139B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 28 | Active |
| US11141378B2 | Lipid formulations for nucleic acid delivery | Chemistry; Metallurgy | 28 | Active |
| US9636301B2 | In vitro release assay for liposome encapsulated vincristine | Physics | 27 | Active |
| US10653780B2 | Amino lipids and methods for the delivery of nucleic acids | Emerging Cross-Sectional Technologies | 18 | Active |
| US9687550B2 | Compositions for nucleic acid delivery | Chemistry; Metallurgy | 12 | Active |
| US10077232B2 | Cyclic cationic lipids and methods of use | Chemistry; Metallurgy | 12 | Active |
| US10117941B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 10 | Active |
| US10053689B2 | Methods for increasing efficacy of lipid formulated siRNA | Chemistry; Metallurgy | 7 | Active |
| US9764036B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 7 | Active |
| US10415037B2 | Compositions and methods for silencing hepatitis B virus gene expression | Chemistry; Metallurgy | 7 | Active |
| US9814777B2 | Targeting lipids | Emerging Cross-Sectional Technologies | 7 | Active |
| US10456473B2 | Lipid compositions | Emerging Cross-Sectional Technologies | 6 | Active |
| US10561732B2 | Trialkyl cationic lipids and methods of use thereof | Chemistry; Metallurgy | 4 | Active |
| US11191849B2 | Compositions and methods for delivering messenger RNA | Chemistry; Metallurgy | 4 | Active |
| US10821186B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 4 | Active |
| US9707292B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 4 | Active |
| US11718852B2 | Non-liposomal systems for nucleic acid delivery | Chemistry; Metallurgy | 3 | Active |
| US9694077B2 | Lipid compositions | Emerging Cross-Sectional Technologies | 3 | Active |
| US11446383B2 | Lipid formulations for delivery of therapeutic agents | Emerging Cross-Sectional Technologies | 3 | Active |
| US11786598B2 | Lipid formulations for delivery of therapeutic agents | Emerging Cross-Sectional Technologies | 3 | Active |
| US10358447B2 | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same | Human Necessities | 2 | Active |
| US9895448B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | Chemistry; Metallurgy | 2 | Active |
| US11077197B2 | Lipids and compositions for the delivery of therapeutics | Emerging Cross-Sectional Technologies | 2 | Active |
| US11427823B2 | Targeted compositions | Chemistry; Metallurgy | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.